In the phase II study on BGJ398 in advanced CCA, only 1 of 3 cases with FGFR2 amplification showed a reduction in tumor size (by 27%).15 Similarly, in the same trial, only 1 of 8 cases with FGFR2 mutation showed reduction in size (by 23%). The gene discussed is FGFR2; the disease is cholangiocarcinoma.